# SABR PRIMER - Evaluating Stereotactic Ablative Radiotherapy for Primary and Regional Breast Tumors

> **NCT06937281** · NA · NOT_YET_RECRUITING · sponsor: **British Columbia Cancer Agency** · enrollment: 40 (estimated)

## Conditions studied

- Breast Cancer
- Metastases

## Interventions

- **RADIATION:** SABR

## Key facts

- **NCT ID:** NCT06937281
- **Lead sponsor:** British Columbia Cancer Agency
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2025-07-01
- **Primary completion:** 2029-06-30
- **Final completion:** 2030-07-30
- **Target enrollment:** 40 (ESTIMATED)
- **Last updated:** 2025-04-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06937281

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06937281, "SABR PRIMER - Evaluating Stereotactic Ablative Radiotherapy for Primary and Regional Breast Tumors". Retrieved via AI Analytics 2026-07-10 from https://api.ai-analytics.org/clinical/NCT06937281. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*